Mercy Catholic Medical Center

LDL-C vs Lp(a): What We Know, the “Zero-LDL” Hypothesis, and Where We Stand in the PCSK9 Era

Despite significant breakthroughs in preventative medicine, atherosclerotic cardiovascular disease (ASCVD) is still the primary cause of morbidity and death worldwide. In this context, 2 apoB-containing particles-LDL and lipoprotein(a) [Lp(a)] have emerged as important but mechan...

Osimertinib-Associated Cardiotoxicity in EGFR-Mutant Non–Small Cell Lung Cancer: Mechanisms, Phenotypes, and Surveillance

Osimertinib, a third-generation EGFR-TKI, is now the standard first-line treatment for EGFR-mutant non–small cell lung cancer and is increasingly given in the adjuvant setting for up to 3 years and in combination with chemotherapy. As exposure has lengthened and shifted toward cu...